← Back to Search

Distress Tolerance - Benzodiazepine Discontinuation (DT-BD) for Substance Use Disorder (DT-BD Trial)

N/A

Waitlist Available

Led By Tae Woo Park, MD

Research Sponsored by University of Pittsburgh

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 4- and 6-months

Awards & highlights

DT-BD Trial Summary

This trial will test a new intervention to help people on opioids who also use benzodiazepines to stop using the latter.

Eligible Conditions

Substance Use Disorder

DT-BD Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 4- and 6-months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~4- and 6-months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 4- and 6-months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of participants who discontinued BZDs at 4-month follow-up

Number of participants who discontinued BZDs at 6-month follow-up

Secondary outcome measures

Change in distress tolerance

Change in quantity of BZD use

Other outcome measures

Anxiety symptoms

BZD withdrawal symptoms

Depressive symptoms

+3 more

DT-BD Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Distress Tolerance - Benzodiazepine Discontinuation (DT-BD)Experimental Treatment1 Intervention

This psychosocial treatment intervention uses a combination of interoceptive exposure therapy and elements of acceptance and commitment therapy (ACT) and psychoeducation about benzodiazepine use in OAT.

Group II: Relaxation TherapyActive Control1 Intervention

The relaxation therapy control condition involves psychoeducation about benzodiazepine use in OAT and progressive muscle-relaxation training.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Distress Tolerance - Benzodiazepine Discontinuation (DT-BD)

2021

Completed Phase 2

~10

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of PittsburghLead Sponsor

1,719 Previous Clinical Trials

16,342,340 Total Patients Enrolled

National Institute on Drug Abuse (NIDA)NIH

2,465 Previous Clinical Trials

2,618,632 Total Patients Enrolled

Tae Woo Park, MDPrincipal InvestigatorUniversity of Pittsburgh

2 Previous Clinical Trials

119 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the research currently seeking participants?

"The details recorded on clinicaltrials.gov indicate that this research is currently recruiting patients, having initially been posted to the website in mid-June of 2022 and most recently updated at the beginning of August."

Answered by AI

How many people have volunteered for this medical experiment?

"Affirmative. As found on the clinicaltrials.gov website, this experiment is currently enrolling volunteers and was initially posted on June 17th 2022. A total of 50 individuals are needed across 3 distinct locations to complete the study's requirements with a recent update occurring on August 2nd 2022."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Distress Tolerance for Benzodiazepine Discontinuation

Tae Woo Park 2022. "Distress Tolerance for Benzodiazepine Discontinuation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05250570.